PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells

Chemotherapy is one of the main therapeutic modalities for cancer patients. Cisplatin (CDDP), as one of the first-line drugs, is of great importance in the chemotherapy of various tumors. However, a significant percentage of cancer patients are resistant to CDDP treatment. Due to the CDDP side effects on normal tissues, the diagnosis of CDDP resistance is required to suggest the most efficient therapeutic strategies for cancer patients. Several molecular mechanisms and signaling pathways are associated with CDDP response. The PI3K/AKT signaling pathway has a pivotal role in the transmission of extracellular signals into the cells to regulate various pathophysiological processes such as cell proliferation, migration, and drug resistance. In the present review, we summarized all of the studies which have been reported on the role of PI3K/AKT pathway in regulation of CDDP response. It was shown that the PI3K/AKT pathway is mainly involved in CDDP response in lung, ovarian, and gastrointestinal cancers. It was also observed that the non-coding RNAs have a key role in CDDP response by regulation of PI3K/AKT pathway. This review paves the way for suggesting a PI3K/AKT-related panel marker for the prediction of CDDP response in different cancer patients.

[1]  M. Moghbeli,et al.  Long non-coding RNAs as the critical regulators of epithelial mesenchymal transition in colorectal tumor cells: an overview , 2022, Cancer Cell International.

[2]  M. Moghbeli,et al.  Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells , 2021, Cellular & molecular biology letters.

[3]  M. Moghbeli.  Molecular interactions of miR-338 during tumor progression and metastasis , 2021, Cellular & molecular biology letters.

[4]  Qingfeng Ni,et al.  MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling , 2021, Aging.

[5]  Xuan Wei,et al.  Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway , 2020, Frontiers in Oncology.

[6]  Guanrong Wang,et al.  MNAT1 promotes proliferation and the chemo-resistance of osteosarcoma cell to cisplatin through regulating PI3K/Akt/mTOR pathway , 2020, BMC Cancer.

[7]  M. Mojarrad,et al.  Non coding RNAs as the critical factors in chemo resistance of bladder tumor cells , 2020, Diagnostic Pathology.

[8]  Tong Wang,et al.  Circadian Clock Protein PERIOD2 Suppresses the PI3K/Akt Pathway and Promotes Cisplatin Sensitivity in Ovarian Cancer , 2020, Cancer management and research.

[9]  Yugang Wang,et al.  FOXD1‐AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway , 2020, Molecular oncology.

[10]  Lizhen Liu,et al.  XPD inhibits cell growth and invasion and enhances chemosensitivity in esophageal squamous cell carcinoma by regulating the PI3K/AKT signaling pathway , 2020, International journal of molecular medicine.

[11]  Hao Chen,et al.  Ubiquitin-specific peptidase 17 promotes cisplatin resistance via PI3K/AKT activation in non-small cell lung cancer , 2020, Oncology letters.

[12]  Song Zhang,et al.  SDC1 promotes cisplatin resistance in hepatic carcinoma cells via PI3K-AKT pathway , 2020, Human Cell.

[13]  Chen Li,et al.  LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K/AKT pathway , 2020, Journal of Cancer.

[14]  Chen Li,et al.  LncRNA MALAT1 Regulates the Cell Proliferation and Cisplatin Resistance in Gastric Cancer via PI3K/AKT Pathway , 2020, Cancer management and research.

[15]  M. Mojarrad,et al.  Long non-coding RNAs as the critical factors during tumor progressions among Iranian population: an overview , 2020, Cell & Bioscience.

[16]  Shidai Jin,et al.  miR-1269b Drives Cisplatin Resistance of Human Non-Small Cell Lung Cancer via Modulating the PTEN/PI3K/AKT Signaling Pathway , 2020, OncoTargets and therapy.

[17]  Tianhao Xie,et al.  Ghrelin inhibits cisplatin-induced MDA-MB-231 breast cancer cell apoptosis via PI3K/Akt/mTOR signaling , 2019, Experimental and therapeutic medicine.

[18]  Xihui Wang,et al.  AFAP1-AS1 induces cisplatin resistance in non-small cell lung cancer through PI3K/AKT pathway , 2019, Oncology letters.

[19]  Tongtong Gong,et al.  CDKL5 promotes proliferation, migration, and chemotherapeutic drug resistance of glioma cells via activation of the PI3K/AKT signaling pathway , 2019, FEBS open bio.

[20]  A. Sarasin,et al.  XPD/ERCC2 mutations interfere in cellular responses to oxidative stress. , 2019, Mutagenesis.

[21]  Gong Yang,et al.  The crosstalk between STAT3 and p53/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy , 2019, Oncogenesis.

[22]  Song Zhao,et al.  miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway , 2019, Cancer Cell International.

[23]  Yunlong Wang,et al.  ALC1 knockdown enhances cisplatin cytotoxicity of esophageal squamous cell carcinoma cells by inhibition of glycolysis through PI3K/Akt pathway. , 2019, Life sciences.

[24]  Surong Zhao,et al.  miR-205-5p regulates epithelial-mesenchymal transition by targeting PTEN via PI3K/AKT signaling pathway in cisplatin-resistant nasopharyngeal carcinoma cells. , 2019, Gene.

[25]  Hai Hu,et al.  Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells , 2019, Technology in cancer research & treatment.

[26]  H. Zhang,et al.  SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway. , 2019, European review for medical and pharmacological sciences.

[27]  A. El‐kott,et al.  Acylated Ghrelin Renders Chemosensitive Ovarian Cancer Cells Resistant to Cisplatin Chemotherapy via Activation of the PI3K/Akt/mTOR Survival Pathway , 2019, Analytical cellular pathology.

[28]  Yong Li,et al.  Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression , 2019, BMC Cancer.

[29]  Ting Zhang,et al.  The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling , 2019, Cell Death & Disease.

[30]  M. Abbaszadegan,et al.  Role of MAML1 in targeted therapy against the esophageal cancer stem cells , 2019, Journal of Translational Medicine.

[31]  Ju Chen,et al.  Glutathione Peroxidase 1 Promotes NSCLC Resistance to Cisplatin via ROS-Induced Activation of PI3K/AKT Pathway , 2019, BioMed research international.

[32]  B. Liu,et al.  A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway. , 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[33]  Yuan-qi Shi,et al.  XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells. , 2019, Oncology reports.

[34]  Binbin Gao,et al.  LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway. , 2019, European review for medical and pharmacological sciences.

[35]  Pei Li,et al.  Long noncoding RNA OIP5‐AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR‐340‐5p , 2018, Journal of cellular biochemistry.

[36]  D. Xiong,et al.  SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines , 2019, Cancer Chemotherapy and Pharmacology.

[37]  M. Abbaszadegan,et al.  ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer , 2019, Biological Research.

[38]  X. Shen,et al.  MALAT1 promotes cisplatin resistance in cervical cancer by activating the PI3K/AKT pathway. , 2018, European review for medical and pharmacological sciences.

[39]  R. Weinberg,et al.  New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer , 2018, Nature reviews. Molecular cell biology.

[40]  C. Dang,et al.  Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1 , 2018, International journal of oncology.

[41]  M. Abbaszadegan,et al.  WNT and NOTCH signaling pathways as activators for epidermal growth factor receptor in esophageal squamous cell carcinoma , 2018, Cellular & Molecular Biology Letters.

[42]  Xueping Wang,et al.  Neogenin-1 Promotes Cell Proliferation, Motility, and Adhesion by Up-Regulation of Zinc Finger E-Box Binding Homeobox 1 Via Activating the Rac1/PI3K/AKT Pathway in Gastric Cancer Cells , 2018, Cellular Physiology and Biochemistry.

[43]  Y. Li,et al.  HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells. , 2018, Gene.

[44]  Liuqing Cui,et al.  Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway , 2018, Journal of translational medicine.

[45]  M. Gottesman,et al.  Revisiting the role of ABC transporters in multidrug-resistant cancer , 2018, Nature Reviews Cancer.

[46]  C. Ding,et al.  Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR. , 2018, Oncology reports.

[47]  Wei Chen,et al.  HSPA12B overexpression induces cisplatin resistance in non-small-cell lung cancer by regulating the PI3K/Akt/NF-κB signaling pathway. , 2018, Oncology letters.

[48]  F. Wandosell,et al.  Role of Akt Isoforms Controlling Cancer Stem Cell Survival, Phenotype and Self-Renewal , 2018, Biomedicines.

[49]  Jiangang Liu,et al.  miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway , 2018, Oncology reports.

[50]  Cong Wang,et al.  RACKI induces chemotherapy resistance in esophageal carcinoma by upregulating the PI3K/AKT pathway and Bcl-2 expression , 2018, OncoTargets and therapy.

[51]  Jiwei Yu,et al.  Interaction between CD133 and PI3K-p85 promotes chemoresistance in gastric cancer cells. , 2018, American journal of translational research.

[52]  M. H. Sangtarash,et al.  MiR-221/222 promote chemoresistance to cisplatin in ovarian cancer cells by targeting PTEN/PI3K/AKT signaling pathway , 2018, Cytotechnology.

[53]  I. Berindan‐Neagoe,et al.  The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression , 2018, Cell Death & Disease.

[54]  I. Shin,et al.  Silencing of Glut1 induces chemoresistance via modulation of Akt/GSK-3β/β-catenin/survivin signaling pathway in breast cancer cells. , 2017, Archives of biochemistry and biophysics.

[55]  A. Hamacher,et al.  Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38 , 2017, BMC Cancer.

[56]  Yuxin Tang,et al.  Knockdown of HMGN5 increases the chemosensitivity of human urothelial bladder cancer cells to cisplatin by targeting PI3K/Akt signaling , 2017, Oncology letters.

[57]  Qiong Chen,et al.  GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[58]  A. Oberst,et al.  Mitochondrial permeabilisation engages NF-κB dependent anti-tumour activity under caspase deficiency , 2017, Nature Cell Biology.

[59]  Yufeng Tang,et al.  Knockdown of HIF-1α by siRNA-expressing plasmid delivered by attenuated Salmonella enhances the antitumor effects of cisplatin on prostate cancer , 2017, Scientific Reports.

[60]  Lovelace J. Luquette,et al.  A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. , 2017, Cancer cell.

[61]  P. Salomoni,et al.  mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism , 2017, Cell Death and Differentiation.

[62]  Wei Zhang,et al.  Reduced expression of miR‑205‑5p promotes apoptosis and inhibits proliferation and invasion in lung cancer A549 cells by upregulation of ZEB2 and downregulation of erbB3. , 2017, Molecular medicine reports.

[63]  Zhi Huang,et al.  Expression of Long Noncoding RNA Urothelial Cancer Associated 1 Promotes Cisplatin Resistance in Cervical Cancer. , 2017, Cancer biotherapy & radiopharmaceuticals.

[64]  M. Abbaszadegan,et al.  TWIST1 upregulates the MAGEA4 oncogene , 2017, Molecular carcinogenesis.

[65]  E. Wang,et al.  Derlin-1 overexpression confers poor prognosis in muscle invasive bladder cancer and contributes to chemoresistance and invasion through PI3K/AKT and ERK/MMP signaling , 2017, Oncotarget.

[66]  B. Manavathi,et al.  HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation , 2016, Cellular Oncology.

[67]  Jing Liu,et al.  A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway , 2016, Journal of Hematology & Oncology.

[68]  W. Duan,et al.  Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer , 2016, Oncotarget.

[69]  R. Kitazawa,et al.  TDRG1 regulates chemosensitivity of seminoma TCam-2 cells to cisplatin via PI3K/Akt/mTOR signaling pathway and mitochondria-mediated apoptotic pathway , 2016, Cancer biology & therapy.

[70]  Niu Zhanfeng,et al.  Period2 downregulation inhibits glioma cell apoptosis by activating the MDM2-TP53 pathway , 2016, Oncotarget.

[71]  J. Marin,et al.  Mechanisms of Resistance to Chemotherapy in Gastric Cancer. , 2016, Anti-cancer agents in medicinal chemistry.

[72]  Xiaochen Li,et al.  KLF5 mediates vascular remodeling via HIF-1α in hypoxic pulmonary hypertension. , 2016, American journal of physiology. Lung cellular and molecular physiology.

[73]  Mengwei Zhang,et al.  HPIP promotes non-small cell lung cancer cell proliferation, migration and invasion through regulation of the Sonic hedgehog signaling pathway. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[74]  Yuxin Tang,et al.  TDRG1 functions in testicular seminoma are dependent on the PI3K/Akt/mTOR signaling pathway , 2016, OncoTargets and therapy.

[75]  Feng Li,et al.  PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells , 2015, Clinical and experimental pharmacology & physiology.

[76]  He Sun,et al.  PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway , 2015, Diagnostic Pathology.

[77]  A. Shteingauz,et al.  Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy. , 2015, Cancer research.

[78]  Mengzhong Liu,et al.  Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival , 2015, Oncotarget.

[79]  Han Liu,et al.  Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation , 2015, Autophagy.

[80]  X. Liang,et al.  Prostaglandin transporter, SLCO2A1, mediates the invasion and apoptosis of lung cancer cells via PI3K/AKT/mTOR pathway. , 2015, International journal of clinical and experimental pathology.

[81]  E. Kikuchi,et al.  Nicotine Induces Tumor Growth and Chemoresistance through Activation of the PI3K/Akt/mTOR Pathway in Bladder Cancer , 2015, Molecular Cancer Therapeutics.

[82]  Hong Zhu,et al.  The Down-Regulation of MicroRNA-497 Contributes to Cell Growth and Cisplatin Resistance Through PI3K/Akt Pathway in Osteosarcoma , 2015, Cellular Physiology and Biochemistry.

[83]  Lan Shen,et al.  Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway , 2015, Apoptosis.

[84]  Xinbing Sui,et al.  The role of STAT3 in autophagy , 2015, Autophagy.

[85]  J. Qu,et al.  LRIG1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells , 2015, Cell Stress and Chaperones.

[86]  Longgui Wang,et al.  Rab25 is responsible for phosphoinositide 3-kinase/AKT‑mediated cisplatin resistance in human epithelial ovarian cancer cells. , 2015, Molecular medicine reports.

[87]  P. Tchounwou,et al.  Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.

[88]  Sun-Mi Park,et al.  VEGF‐C mediates RhoGDI2‐induced gastric cancer cell metastasis and cisplatin resistance , 2014, International journal of cancer.

[89]  Di Wu,et al.  Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro. , 2014, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[90]  D. Xie,et al.  RACK1, a versatile hub in cancer , 2014, Oncogene.

[91]  E. Bellolio,et al.  The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance , 2014, Virchows Archiv.

[92]  Gopal Chakrabarti,et al.  miR-17-5p Downregulation Contributes to Paclitaxel Resistance of Lung Cancer Cells through Altering Beclin1 Expression , 2014, PloS one.

[93]  C. Porta,et al.  Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..

[94]  Jiarui Feng,et al.  PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/Erk-dependent pathways. , 2014, Bioscience reports.

[95]  M. Ohmura,et al.  Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway , 2014, Nature Communications.

[96]  Wen-jie Zheng,et al.  Synergistic induction of apoptosis by methylseleninic acid and cisplatin, the role of ROS-ERK/AKT-p53 pathway. , 2014, Molecular pharmaceutics.

[97]  H. Brinkhaus,et al.  MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation , 2014, Cell Death and Differentiation.

[98]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[99]  P. Bie,et al.  Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT. , 2014, Toxicology letters.

[100]  W. Chazin,et al.  Xeroderma pigmentosum complementation group C protein (XPC) serves as a general sensor of damaged DNA. , 2013, DNA repair.

[101]  K. Mimori,et al.  Paired related homoeobox 1, a new EMT inducer, is involved in metastasis and poor prognosis in colorectal cancer , 2013, British Journal of Cancer.

[102]  Cheng Huang,et al.  miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. , 2013, Toxicology.

[103]  W. Xu,et al.  Klotho Sensitizes Human Lung Cancer Cell Line to Cisplatin via PI3k/Akt Pathway , 2013, PloS one.

[104]  C. Xiao,et al.  MicroRNA-221 Induces Cell Survival and Cisplatin Resistance through PI3K/Akt Pathway in Human Osteosarcoma , 2013, PloS one.

[105]  H. Lincet,et al.  A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. , 2012, Biochimica et biophysica acta.

[106]  C. Messini,et al.  Ghrelin , 2012, Reproductive Sciences.

[107]  J. Chien,et al.  HtrA1 sensitizes ovarian cancer cells to cisplatin‐induced cytotoxicity by targeting XIAP for degradation , 2012, International journal of cancer.

[108]  D. Spandidos,et al.  Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). , 2011, International journal of oncology.

[109]  Hyun-Seok Kim,et al.  Sensitization of epithelial growth factor receptors by nicotine exposure to promote breast cancer cell growth , 2011, Breast Cancer Research.

[110]  J. F. Burrows,et al.  The deubiquitinating enzyme USP17 is essential for GTPase subcellular localization and cell motility , 2011, Nature communications.

[111]  J. Grandis,et al.  STAT3 signaling: anticancer strategies and challenges. , 2011, Molecular interventions.

[112]  Y. Tsai,et al.  The effect of component of microemulsion for transdermal delivery of nicardipine hydrochloride , 2010, Drug development and industrial pharmacy.

[113]  M. Stepp,et al.  Syndecan-1 regulates cell migration and fibronectin fibril assembly. , 2010, Experimental cell research.

[114]  G. Kouraklis,et al.  Ghrelin: A potential therapeutic target for cancer , 2010, Regulatory Peptides.

[115]  J. F. Burrows,et al.  The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression. , 2010, Cancer research.

[116]  Gen Sheng Wu,et al.  Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. , 2010, Biochemical and biophysical research communications.

[117]  D. Ross,et al.  Impact of breast cancer resistance protein on cancer treatment outcomes. , 2010, Methods in molecular biology.

[118]  M. Bustin,et al.  HMGN5/NSBP1: a new member of the HMGN protein family that affects chromatin structure and function. , 2010, Biochimica et biophysica acta.

[119]  Jean-Pierre Gillet,et al.  Mechanisms of multidrug resistance in cancer. , 2010, Methods in molecular biology.

[120]  Jian-ming Zeng,et al.  Per2 Inhibits K562 Leukemia Cell Growth In Vitro and In Vivo Through Cell Cycle Arrest and Apoptosis Induction , 2010, Pathology & Oncology Research.

[121]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[122]  D. Klionsky,et al.  Regulation mechanisms and signaling pathways of autophagy. , 2009, Annual review of genetics.

[123]  G. Mills,et al.  The Emerging Role of the RAB25 Small GTPase in Cancer , 2009, Traffic.

[124]  S. Hirohashi,et al.  Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer. , 2009, Cancer letters.

[125]  J. Chien,et al.  HtrA serine proteases as potential therapeutic targets in cancer. , 2009, Current cancer drug targets.

[126]  M. Czaja,et al.  Autophagy regulates lipid metabolism , 2009, Nature.

[127]  M. Naujokas,et al.  Pak4, a Novel Gab1 Binding Partner, Modulates Cell Migration and Invasion by the Met Receptor , 2009, Molecular and Cellular Biology.

[128]  Chun-Yin Huang,et al.  CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. , 2009, Biochemical pharmacology.

[129]  B. Karlan,et al.  Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer , 2008, Oncogene.

[130]  Wolfgang Link,et al.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. , 2008, Current cancer drug targets.

[131]  Daniel J. Klionsky,et al.  Autophagy fights disease through cellular self-digestion , 2008, Nature.

[132]  Jie Xu,et al.  Nicotine inhibits apoptosis induced by cisplatin in human oral cancer cells. , 2007, International journal of oral and maxillofacial surgery.

[133]  J. McCubrey,et al.  Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts , 2007, Leukemia.

[134]  X. Chang.  A molecular understanding of ATP-dependent solute transport by multidrug resistance-associated protein MRP1 , 2007, Cancer and Metastasis Reviews.

[135]  C. R. Wilson,et al.  Ménage-à-Trois 1 Is Critical for the Transcriptional Function of PPARγ Coactivator 1 , 2007 .

[136]  Nicole H. Wilson,et al.  Neogenin: one receptor, many functions. , 2007, The international journal of biochemistry & cell biology.

[137]  Rakesh Kumar,et al.  An inherent role of microtubule network in the action of nuclear receptor , 2006, Proceedings of the National Academy of Sciences.

[138]  T. Takahashi,et al.  NNK activates ERK1/2 and CREB/ATF-1 via beta-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells. , 2006, International journal of cancer.

[139]  T Nakazato,et al.  Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. , 2006, European journal of cancer.

[140]  R. Batey,et al.  Targeting XIAP for the treatment of malignancy , 2006, Cell Death and Differentiation.

[141]  R. Stahel,et al.  Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation , 2005, International journal of cancer.

[142]  René Bernards,et al.  A Genomic and Functional Inventory of Deubiquitinating Enzymes , 2005, Cell.

[143]  C. Thompson,et al.  ATP citrate lyase is an important component of cell growth and transformation , 2005, Oncogene.

[144]  N. Hay,et al.  The Akt-mTOR tango and its relevance to cancer. , 2005, Cancer cell.

[145]  D. Nguyen,et al.  Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions. , 2005, Cancer research.

[146]  Dong-Hyun Kim,et al.  Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. , 2005, Gynecologic oncology.

[147]  G. Ehninger,et al.  MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia , 2005, British journal of haematology.

[148]  Anupama E. Gururaj,et al.  Regulation of phosphoglucomutase 1 phosphorylation and activity by a signaling kinase , 2004, Oncogene.

[149]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[150]  H. Ploegh,et al.  A membrane protein required for dislocation of misfolded proteins from the ER , 2004, Nature.

[151]  C. Tokunaga,et al.  mTOR integrates amino acid- and energy-sensing pathways. , 2004, Biochemical and biophysical research communications.

[152]  T. Nheu,et al.  PAK Is Essential for RAS-Induced Upregulation of Cyclin D1 During the G1 to S Transition , 2004, Cell cycle.

[153]  M. Marangolo,et al.  Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer. , 2003, Journal of experimental & clinical cancer research : CR.

[154]  G. Bokoch.  Biology of the p21-activated kinases. , 2003, Annual review of biochemistry.

[155]  Brendan M Leung,et al.  p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. , 2003, Cancer research.

[156]  Wonhwa Cho,et al.  Membrane-binding and activation mechanism of PTEN , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[157]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[158]  J. Warwicker,et al.  The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. , 2002, Molecular pharmacology.

[159]  C. Abate-Shen.  Deregulated homeobox gene expression in cancer: cause or consequence? , 2002, Nature Reviews Cancer.

[160]  P. Krammer,et al.  Tumor Immunology , 2018, Medical Immunology.

[161]  B. Griffith,et al.  P‐glycoprotein (P‐gp) Is Upregulated in Peripheral T‐Cell Subsets from Solid Organ Transplant Recipients , 2001, Journal of clinical pharmacology.

[162]  J C Reed,et al.  The Survivin saga goes in vivo. , 2001, The Journal of clinical investigation.

[163]  D R Alessi,et al.  PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? , 2001, Journal of cell science.

[164]  J. Hayakawa,et al.  Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. , 2000, Cancer research.

[165]  P. McHugh,et al.  Defining the Roles of Nucleotide Excision Repair and Recombination in the Repair of DNA Interstrand Cross-Links in Mammalian Cells , 2000, Molecular and Cellular Biology.

[166]  H. Wu,et al.  PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[167]  J. Meléndez-Zajgla,et al.  Mitochondrial changes during the apoptotic process of HeLa cells exposed to cisplatin , 1999, Biochemistry and molecular biology international.

[168]  G. Wang,et al.  Induction of the , 1996 .